Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

"Maintenance (until progression, unacceptable toxicity or if CR \> 1 year, as per investigator choice)~Avelumab 10 mg/kg every 2 weeks (±3 days)"

"Maintenance (until progression, unacceptable toxicity or if CR \> 1 year, as per investigator choice)~Cetuximab 500 mg/m² every 2 weeks (±3 days) (according to current recommendations \[35\])"